<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01643083</url>
  </required_header>
  <id_info>
    <org_study_id>HKU_RD1</org_study_id>
    <nct_id>NCT01643083</nct_id>
  </id_info>
  <brief_title>Rifaximin for Functional Dyspepsia</brief_title>
  <official_title>Use of Rifaximin in Patients With Functional Dyspepsia: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Hong Kong</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Functional dyspepsia is a very common medical condition, which occurs in up to 30% of people
      in the community. However, results of current pharmacological treatment on functional
      dyspepsia are unsatisfactory. Rifaximin is a minimally absorbed antibiotic that has been used
      in treatment of non-constipated irritable bowel syndrome (IBS). In particular, bloating and
      abdominal pain was improved by rifaximin treatment in this group of IBS patients. Whilst
      there is considerable overlap in symptoms of functional dyspepsia and IBS, the investigators
      test whether rifaximin is also effective in curing post-prandial distress symptoms related to
      dyspepsia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is to test the effects of rifaximin, a minimally absorbed antibiotics,
      on symptoms of patients with functional dyspepsia.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adequate relief of dyspeptic symptoms at end of treatment</measure>
    <time_frame>end of treatment (week 2)</time_frame>
    <description>global symptom improvement</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Individual dyspeptic symptom scores</measure>
    <time_frame>week 2, 4 and 8</time_frame>
    <description>Hong Kong Dyspeptic Index</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">95</enrollment>
  <condition>Functional Dyspepsia</condition>
  <arm_group>
    <arm_group_label>Rifaximin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifaximin</intervention_name>
    <description>Rifaximin 400mg tid for 2 wk</description>
    <arm_group_label>Rifaximin</arm_group_label>
    <other_name>Normix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo for 2 week</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Non-ulcer dyspeptic patients who fulfill post-prandial distress syndrome according to
             the Rome III Criteria

          -  Active dyspeptic symptom

          -  Normal upper endoscopy

          -  Urea Breath Test -ve or Rapid urease test -ve

          -  Not typical gastroesophageal reflux or biliary colic symptoms, but presence of
             infrequent acid reflux is allowed

        Exclusion Criteria:

          -  No active dyspeptic symptom

          -  Allergic to rifaximin

          -  Recent antibiotics use in the past 8 wk

          -  Recent PPI or H2RA in past 4 wk

          -  On anti-coagulants, anti-convulsant or oral contraceptives

          -  On NSAIDs, aspirin or Clopidogrel

          -  Pregnancy or breast feeding

          -  Previous gastric surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wai Keung Leung, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Hong Kong</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Queen Mary Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 15, 2012</study_first_submitted>
  <study_first_submitted_qc>July 16, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 17, 2012</study_first_posted>
  <last_update_submitted>November 30, 2015</last_update_submitted>
  <last_update_submitted_qc>November 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Hong Kong</investigator_affiliation>
    <investigator_full_name>LEUNG Wai Keung</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>Post-prandial distress syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyspepsia</mesh_term>
    <mesh_term>Gastritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rifaximin</mesh_term>
    <mesh_term>Rifamycins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

